Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Body Imaging

Review of COVID-19, part 1: Abdominal manifestations in adults and multisystem inflammatory syndrome in children

Devaraju Kanmaniraja a,*, Jessica Kurian a, Justin Holder a, Molly Somberg Gunther a, Victoria Chernyak b, Kevin Hsu a, Jimmy Lee a, Andrew Mcclelland a, Shira E. Slasky a, Jenna Le a, Zina J. Ricci a

a Department of Radiology, Montefiore Medical Center/Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467, United States of America

b Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America

ARTICLE INFO

Keywords:
Abdominal imaging
COVID-19
Multisystem inflammatory syndrome

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has affected almost every country in the world, resulting in severe morbidity, mortality and economic hardship, and altering the landscape of healthcare forever. Although primarily a pulmonary illness, it can affect multiple organ systems throughout the body, sometimes with devastating complications and long-term sequelae. As we move into the second year of this pandemic, a better understanding of the pathophysiology of the virus and the varied imaging findings of COVID-19 in the involved organs is crucial to better manage this complex multi-organ disease and to help improve overall survival. This manuscript provides a comprehensive overview of the pathophysiology of the virus along with a detailed and systematic imaging review of the extra-thoracic manifestation of COVID-19 with the exception of unique cardiothoracic features associated with multisystem inflammatory syndrome in children (MIS-C). In Part I, extra-thoracic manifestations of COVID-19 in the abdomen in adults and features of MIS-C will be reviewed. In Part II, manifestations of COVID-19 in the musculoskeletal, central nervous and vascular systems will be reviewed.

1. Abdominal findings of COVID019 in adults

The coronavirus 2019 disease (COVID-19), which originated in Wuhan, China, has quickly become a global pandemic, bringing normal life to a standstill in almost all countries around the world. The severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a novel virus preceded by two other recent coronavirus infections, the severe acute respiratory syndrome coronavirus (SARS-CoV-1) and the Middle Eastern respiratory syndrome coronavirus (MERS-CoV), but it has more far-reaching and devastating consequences. As of March 2021, the COVID-19 pandemic has resulted in over 29 million cases in the United States and over 121 million cases globally. As of April 2021, it is responsible for the deaths of over half a million people in the United States and more than 1½ million worldwide [1]. As the disease has evolved over the past year, so has our understanding of the virus, including its pathophysiology, clinical presentation and imaging manifestations. Although COVID-19 is predominately a pulmonary illness, it is now established to have widespread extra-pulmonary involvement affecting multiple organ systems. The SARS-CoV-2 has a highly virulent spike protein which binds efficiently to the angiotensin converting enzyme 2 (ACE2) receptors which are expressed in many organs, including the airways, lung parenchyma, several organs in the abdomen, particularly the kidneys and GI system, central nervous system and the smooth and skeletal muscles of the body [2]. The virus initially induces a specific adaptive immune response, and when this response is ineffective, it results in uncontrolled inflammation, which ultimately results in tissue injury [2].

This article provides a comprehensive review of the pathophysiology and imaging findings of the extra-thoracic manifestations of COVID-19 with the exception of unique cardiothoracic features associated with multisystem inflammatory syndrome in children (MIS-C). In Part I, extra-thoracic manifestations of COVID-19 in the abdomen in adults and features of MIS-C will be reviewed. In Part II, manifestations of COVID-19 in the musculoskeletal, central nervous and vascular systems will be reviewed.
the varying features of multisystem inflammatory syndrome in children will be reviewed, with imaging findings summarized in Tables 1 and 2. In Part II, manifestations of COVID-19 in the musculoskeletal system, the central nervous system and central and peripheral vascular systems will be reviewed.

### Table 1
Summary of abdominal imaging findings in COVID-19 in adults.

| Organ       | Imaging findings                                                                 |
|-------------|----------------------------------------------------------------------------------|
| Liver       | • Hepatomegaly                                                                   |
|             | • Increased or coarsened echogenicity on US                                      |
|             | • Hypoattenuation on non-contrast or contrast enhanced CT                         |
|             | • Periportal edema and heterogeneous enhancement on CT                           |
|             | • Loss of signal on opposed-phase sequences on MRI                               |
|             | • Portal vein thrombus                                                            |
| Pancreas    | • Features of acute interstitial pancreatitis                                     |
| Biliary Tree| • Biliary ductal dilatation                                                      |
| Kidney      | • Increased or heterogeneous parenchymal echogenicity on US                       |
|             | • Loss of corticomedullary differentiation on US                                   |
|             | • Preserved cortical thickness                                                    |
|             | • Perinephric fat stranding and thickening of Gerota's fascia on CT               |
|             | • Wedge shaped perfusion defects on CT or MRI                                     |
|             | • Thrombus in the renal artery or vein                                            |
| Gallbladder | • Distention                                                                      |
|             | • Mural edema                                                                    |
|             | • Sludge                                                                         |
|             | • Acalculous cholecystitis                                                       |
| Urinary     | • Bladder wall thickening                                                        |
| Bladder     | • Mural hyperenhancement                                                          |
| Bowel       | • Perivesicular stranding                                                        |
|             | • Mural thickening                                                                |
|             | • Ileus                                                                           |
|             | • Fluid-filled colon                                                              |
|             | • Pneumatosis intestinalis                                                       |
|             | • Portal vein gas                                                                 |
|             | • Pneumoperitoneum                                                               |
|             | • Acute mesenteric ischemia                                                       |
|             | • Vascular occlusion (superior mesenteric artery, superior mesenteric vein, or portal vein) |
|             | • Mesenteric fat stranding, ascites                                               |
|             | • Active gastrointestinal bleeding (duodenal or gastric ulcer) on CTA             |
|             | • Clostridium difficile colitis                                                   |
|             | • Ischemic colitis                                                                |
| Spleen      | • Wedge shaped perfusion defects on CT or MRI                                     |
|             | • Thrombus in the splenic artery or vein                                          |

### Table 2
Summary of imaging findings in Multisystem Inflammatory Syndrome in Children.

| Region       | Imaging findings                                                                 |
|--------------|----------------------------------------------------------------------------------|
| Cardiothoracic| • Bilateral symmetric diffuse airspace opacities with lower lobe predominance on CXR |
|              | • Diffuse ground glass opacity, septal thickening, and mild hilar lymphadenopathy on CT |
|              | • Bilateral pleural effusions                                                     |
|              | • Cardiomegaly                                                                   |
|              | • Pericardial effusion                                                           |
|              | • Myocarditis pattern on cardiac MRI                                             |
| Abdominal    | • Mesenteric lymphadenopathy, most common in right lower quadrant                 |
|              | • Mesenteric edema                                                               |
|              | • Ascites                                                                        |
|              | • Bowel wall thickening                                                           |
|              | • Ileus                                                                          |
|              | • Hepatosplenomegaly                                                             |
|              | • Gallbladder wall thickening                                                    |

2. Abdominal findings of COVID-19 in adults

#### 2.1. Hepatobiliary derangement

Varying derangements of the liver, biliary system, gallbladder, portal vein and pancreas may occur in COVID-19 with hepatic parenchymal injury and biliary stasis reported with highest frequency. The mechanism of involvement of these structures appears to be multifactorial. The most direct form of injury results from SARS CoV-2 entry into host cells by binding to ACE2 receptors detected in several locations in the hepatobiliary system, including biliary epithelial cells (cholangiocytes), gallbladder endothelial cells and both pancreatic islet cells and exocrine glands [3-6].

##### 2.1.1. Hepatic injury

Direct SARS CoV-2 entry into cholangiocytes may cause liver damage by disrupting bile acid transportation or by triggering acid accumulation resulting in liver injury [7]. Systemic inflammation, hypoxia inducing hepatitis and adverse drug reactions may incite liver injury [8]. Several drugs commonly used to treat COVID-19 patients, including acetaminophen, lopinavir and ritonavir can be hepatotoxic [9]. One study excluding COVID-19 patients receiving hepatotoxic drugs, still found patients with liver injury. Therefore, liver damage in COVID-19 patients is likely not entirely drug-induced but may also be due to acute infection [8,9]. Furthermore, since patients with chronic liver disease such as cirrhosis, autoimmune liver disease and prior liver transplantation are more susceptible to COVID-19 infection [9], underlying conditions may also contribute to liver injury.

The most frequent hepatic derangement is abnormal liver function tests reported in 16–53% of patients [10,11] and including raised levels of alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase with mild elevation of bilirubin. The majority of cases are mild and self-limited, with severe liver damage rare [7]. Liver injury is most prevalent in the second week of COVID-19 infection, and has a higher incidence in those with gastrointestinal symptoms and more severe infection [9]. Based on a meta-analysis of hepatic autopsy findings of deceased COVID-19 patients in 7 countries, hepatic steatosis (55%), hepatic sinus congestion (35%) and vascular thrombosis (29%) were the most common [10]. In a retrospective study of abdominal imaging findings of 37 COVID-19 patients, 27% who underwent ultrasound had increased hepatic echogenicity considered to represent fatty liver with elevated liver enzymes being the most frequent indication for ultrasound [4]. It should be noted that since obesity is a major risk factor for severe COVID-19 infection, it might contribute to the frequency of steatosis identified on imaging. In another retrospective abdominal sonographic study of 30 ICU patients with COVID-19, the most common finding was hepatomegaly (56%), with most cases having increased hepatic echogenicity and elevated liver function tests [12]. In the only retrospective case-control study of 204 COVID-19 patients who underwent non-contrast chest CT scan, steatosis was found in 31.9% of cases and only 7.1% of controls [13]. Steatosis was based on a single ROI measurement in the right lobe with an attenuation value ≤ 40 HU. However, underlying risk factors for steatosis such as diabetes, obesity, hypertension and abnormal lipid profile, were not available to exclude preexisting conditions leading to steatosis. Finally, unlike in the spleen and kidney where infarcts are reported in COVID-19, hepatic infarction is not a distinct feature. This is likely due to the liver’s unique dual blood supply. On imaging the liver may be enlarged. On ultrasound, the liver of patients with abnormal liver function tests may be coarsened and/or increased in echogenicity (Figs. 1, 2). On CT scan, the liver may be hypoattenuated on non-contrast or contrast-enhanced exam due to steatosis (Fig. 3). Periportal edema and heterogeneity of hepatic enhancement may be seen on contrast-enhanced CT or MRI due to parenchymal inflammation. On MRI, loss of signal on opposed-phase sequences (Fig. 4) may be seen due to steatosis and periportal edema may be conspicuous on T2-weighted images or on contrast-enhanced...
images [7,8,14]. Periportal lymphadenopathy, typical of chronic liver disease, is not reported in COVID-19 [8]. In patients with severe COVID-19 infection, ancillary manifestations of hepatic inflammation and injury, such as parenchymal attenuation changes and abscesses may be seen (Fig. 5).

2.1.2. Portal vein thrombosis

Portal vein thrombosis is not common in COVID-19 with only few reported cases [15-19]. Its mechanism is likely multifactorial. Since ACE2 receptors are present on vascular endothelial cells, direct viral entry can incite coagulopathy [4]. The vascular endothelium can be damaged by inflammatory cytokines, although sepsis-induced coagulopathy and endothelial dysfunction may play a role, especially in patients who are critically ill [3,4]. Adult respiratory distress syndrome (ARDS) and hypoxia can also trigger a generalized thrombotic state by increased blood viscosity and a transcription-factor signaling pathway [3]. Many of those who have severe disease are afflicted with comorbidities such as obesity and malignancy, and critically ill patients are often immobile, all of which may increase thrombotic risk [3]. Microthrombosis within hepatic parenchyma has also been described, with autopsy results revealing thrombosis within the central veins and hepatic sinusoids [7].

On ultrasound, portal vein thrombosis appears as echogenic material within the vein, although it may be anechoic and undetectable in the
controversial. Intravenous antibiotics alone or with percutaneous cholangioplasty, and increased biliary ductal mural thickening and enhancement demonstrated on imaging as extrahepatic or intrahepatic biliary ductal gallbladder findings in 15% and biliary ductal dilatation in 10% [14].

On imaging, biliary stasis may manifest as increased gallbladder distention (typically defined as >/>=5 cm) and sludge, and acalculous cholecystitis is suggested when there is superimposed gallbladder mural thickening and pericholecystic fluid [20] (Fig. 7). Prolonged biliary stasis may obstruct the biliary tree and result in cholangitis. This is demonstrated on imaging as extrahepatic or intrahepatic biliary ductal dilatation, and increased biliary ductal mural thickening and enhancement (Fig. 8). Gallstones should be excluded on ultrasound, as cholelithiasis is a more common cause of biliary infection.

The management of acute cholecystitis in COVID-19 patients is controversial. Intravenous antibiotics alone or with percutaneous cholecystostomy are advocated by many as a bridging agent to cholecystectomy [22] [Fig. 9]. Since it remains unknown the extent to which SARS-CoV-2 remains in the smoke generated by electrosurgery [23], some recommend conservative management [24]. Others advocate an individualized approach based on the severity of cholecystitis and available resources during the pandemic [25].

Imaging plays a role in the diagnosis of cholecystitis as well as in the in detection of complications of percutaneous cholecystostomy. These complications include placement in the wrong site, catheter dislodgement, intraabdominal hemorrhage or bile leak. Fistulization to the liver can develop when catheters are left in for extended periods of time. In order to avoid potential cholecystostomy risks, some institutions offer surgery in COVID-19 patients as first-line therapy [24].

2.1.4. Pancreatic injury

Pancreatic involvement in COVID-19 is much less common than hepatic or biliary involvement, and may occur from direct viral injury or secondary to general inflammation and systemic illness. Pancreatic islet cells contain ACE2 receptors that may permit direct viral entry, while the host immune-mediated cytokine response can also incite pancreatic damage. In a study of 52 patients hospitalized for COVID-19 pneumonia, 9 (17%) had pancreatic injury defined as elevation of amylase or lipase with only one requiring mechanical ventilation. None had clinically severe pancreatitis [26]. In a larger study of hospitalized COVID-19 patients, almost 11% (13 of 121) had elevated pancreatic enzymes [6]. Only 1–2% of patients with mild viral illness had elevated pancreatic enzymes while almost 18% of patients with severe illness had elevated pancreatic enzymes. On CT scan, no patients had evidence of necrosis and only 7.5% (5 of 67) patients with severe illness had imaging evidence of pancreatitis described mainly as focal pancreatic enlargement or dilatation of the pancreatic duct. Although reported cases of pancreatic injury in COVID-19 tend to be mild, the role of pancreatitis in aggravating systemic inflammation, contributing to ARDS or leading to potential chronic pancreatitis later on remains unknown [6]. Recurrent acute pancreatitis has been reported several weeks after resolution of COVID-19 infection [27]. Finally, in two larger retrospective studies of abdominal imaging findings in hospitalized COVID-19 patients [4,14], only one patient had reported pancreatitis [1].

Imaging findings of pancreatitis in COVID-19 patients mimic those in other settings, with CT demonstrating diffuse or focal pancreatic enlargement, decreased pancreatic attenuation due to edema, surrounding fat stranding and indistinct gland margins. MRI shows similar manifestations, with the gland appearing enlarged with poorly defined margins, and with edema and free fluid appearing bright on T2 weighted images (Figs. 10,11).

2.2. Genitourinary derangement

2.2.1. Acute kidney injury

Acute kidney injury (AKI) is a common complication of SARS-CoV-2 infection, seen in about one third of hospitalized COVID-19 patients [28]. Patients with AKI have a higher associated morbidity and mortality with one meta-analysis showing 77% of patients developing a more severe infection, 5% requiring renal replacement therapy and
having an overall increased mortality rate of 50% [29]. Among the patients who developed AKI and survived, only a third recovered renal function at the time of discharge, and about a third of patients failed to recover to baseline even on subsequent follow-up [30]. In addition, patients with chronic renal disease are at a higher risk of developing severe upper respiratory infection and pneumonia following exposure to COVID-19, secondary to their inherent proinflammatory state and diminished immunity [2,31].

The mechanism of kidney injury in COVID-19 is likely multifactorial. Both the increased expression of ACE2 receptors in the kidneys and certain genetic traits and polymorphism of renal ACE2 receptors enable SARS-CoV-2 binding and viral cell entry [32]. The pathogenesis of AKI involves both direct and indirect effects. The direct effect of the virus causes endothelial damage, inflammatory response, coagulopathy and complement activation while the indirect effects are sequelae of the systemic effects of multisystem involvement including hypovolemia, critical care interventions and organ crosstalk [32]. Organ crosstalk is a complex communication network between distant organs that communicate by signaling factors such as cytokines, growth factors and release of damage associated molecular patterns (DAMPs) from injured tissue.
Histologic evaluation of COVID-19 patients has revealed varying types of injury including collapsing glomerulopathy, proximal tubular injury, microthrombi and microangiopathy [32]. On ultrasound, the kidneys of COVID-19 patients with AKI typically demonstrate increased or heterogeneous parenchymal echogenicity, with possible loss of corticomedullary differentiation [7] [Fig. 12]. Involved kidneys typically have preserved cortical thickness, which helps differentiate them from those with chronic kidney disease. Additionally, a combination of nonspecific findings including increased renal parenchymal echogenicity, loss of corticomedullary differentiation, increased resistive indices and decreased color Doppler flow can be seen in COVID-19 patients with collapsing focal segmental glomerulosclerosis [33]. On non-contrast CT, perinephric fat stranding and thickening of Gerota’s fascia correlated with higher serum creatinine levels in patients with AKI, suggesting more severe inflammation and parenchymal injury [34]. Following the administration of contrast, geographic hypodense areas maybe observed in the periphery of the kidneys from hypoperfusion attributed to vasculopathy [35] [Fig. 13].

2.2.2. Cystitis

Increased urinary frequency has been reported in COVID-19 patients. It is believed that expression of ACE2 receptors in the urinary bladder, although not as high as the kidneys, predisposes patients to interstitial or hemorrhagic cystitis. It is unclear whether the receptors are expressed on the basal or luminal bladder surface. However, infection arises both from urine along the luminal surface and from blood via the basal surface [36]. Viral RNA and inflammatory cytokines have been identified in the urine of COVID-19 patients [36-38]. Additionally, endotheliitis may be a factor in local bladder inflammation [36].

Imaging findings include diffuse and irregular bladder wall thickening on ultrasound and diffuse thickening and enhancement of the bladder wall on CT, with adjacent perivesicular stranding [7,39] [Fig. 14].

2.3. Solid organ infarction

Thromboembolic solid organ events in COVID-19 patients can be arterial or venous in origin [40-43]. In a retrospective study of 141 COVID-19 patients with abdominal pain, 18% had solid organ infarct and vascular thrombosis [14]. The mechanism of organ infarction in COVID-19 is likely multifactorial. There is a direct cytopathic effect of SARS-CoV-2 which results in a viral mediated platelet-dependent endothelial inflammation causing endothelial dysfunction and rise in proinflammatory cytokines, leading to an increase in tissue factor expression [40,44,45]. Hypoxia in COVID-19 patients causes increased blood viscosity and the resulting hypoxia inducible transcription factors promote thrombosis [2,46,47]. Additionally, hypercoagulability from increased levels of coagulation factors and antiphospholipid antibodies along with decreased levels of anticoagulation proteins contribute to the increased incidence of thrombotic events in COVID-19 patients [48]. In a study of 82 patients with COVID-19 who underwent imaging, nine patients (11%) had thromboembolic findings, four of which were solid organ insults [19]. Three splenic and one renal infarct were identified with patent vasculature on contrast-enhanced CT. One additional case of renal vein thrombus was reported without reported renal infarct. This supports disseminated microvascular thrombosis in the etiology of solid organ infarction [19].

2.3.1. Renal infarction

Although relatively uncommon, renal infarcts have been reported in COVID-19 patients [40,49]. Based on a retrospective study of 141 COVID-19 patients with abdominal symptoms, the incidence of renal infarct was 5% on CT scans [14].

On ultrasound, renal infarcts appear as wedge shaped heterogeneous hypoechoic areas with decreased or absent perfusion on color Doppler images [7]. On CT and MRI, renal infarcts may appear as geographic focal or multifocal areas of diminished or absent parenchymal
enhancement in one or both kidneys. The renal defects are typically wedge-shaped spanning the cortex and medulla with their apex towards the hilum and extending to the renal capsule. Several days after acute onset they typically have overlying thin capsular enhancement ("rim sign") due to preserved collateral capsular perfusion. Segmental infarcts have a characteristic geographic appearance that follows the distribution of the anterior and posterior branch vessels of the renal artery [50]. On MRI, infarcts vary with age and are usually hypointense on T1-weighted and T2-weighted images acutely, becoming higher in signal on T2-weighted images over the next few days as coagulation necrosis occurs. They may appear hyperintense on T1-weighted images if hemorrhage occurs. Healed or chronic infarcts have progressively decreased signal due to fibrosis and atrophy. There is often loss of normal corticomedullary differentiation in the infarcted segment and corresponding wedge-shaped areas of hypoenhancement on post contrast images [51]. Less commonly, a filling defect may be seen in the renal artery on post-contrast images [Fig. 15] or vein [Fig. 16].

2.3.2. Splenic infarction

Although relatively uncommon, splenic infarcts have been reported in COVID-19 patients. Based on a retrospective study of 141 COVID-19 patients with abdominal symptoms, the incidence of splenic infarct was 5% on CT scans [14]. In an autopsy series studying the spleens of 10 COVID-19 patients, one had splenic infarct [52]. In a case series of 3 patients with abdominal visceral infarction associated with severe COVID-19 infection, two had splenic infarcts [53]. One patient had both multifocal splenic infarcts and unilateral focal renal infarct and the other had small bowel necrosis and massive splenic infarction requiring surgery. Asymptomatic splenic infarct incidentally noted on CT scan performed for suspected pulmonary embolism has also been reported [54].

On CT and MRI, splenic infarcts appear as single or multiple peripheral wedge-shaped hypoenhancing defects, with their apex pointed towards the hilum [Fig. 17]. They can also be rounded or linear in shape. Their appearance varies with age, being vague hypodense areas on CT with mottled enhancement in the first 24 h, and becoming progressively better defined non-enhancing hypodense defects over the next week [55]. On MRI, splenic infarcts are typically hypointense on T1- and T2-weighted images without enhancement on the post contrast images. However, their appearance varies based on the presence of hemorrhage and with their age. Acute and hemorrhagic infarcts are hyperintense on T1-weighted images and hypointense on T2-weighted images. Subacute infarcts have fluid signal. Chronic infarcts may fully resolve or become hypointense on T2 and T2-weighted images [56,57]. Less commonly, a filling defect may be seen in the splenic vein or artery on post-contrast images [Fig. 18].

2.4. Gastrointestinal derangement

The mechanism of SARS-CoV-2 induced gastrointestinal symptoms is not fully understood and may in part be due to direct viral entry into enterocytes. A single-cell transcriptomic study of enteric and lung cells determined that co-expression of ACE2 and TMPRSS2 cell receptors is necessary to permit SARS-CoV-2 entry. Co-expression was found not only in the lung but also in the esophageal upper epithelial and gland cells, the ileum and colon [58].
Fig. 9. 60-year-old man with history of hypertension and asthma hospitalized for COVID-19 pneumonia with respiratory distress requiring oxygen supplementation and with diffuse abdominal pain and leukocytosis. (a) Axial CT image with lung windows shows bibasilar infiltrates. (b,c) Axial and coronal contrast-enhanced CT images show a hydropic gallbladder with stones (arrow). Hepatobiliary iminodiacetic acid (HIDA) scan was positive confirming acute cholecystitis. Percutaneous cholecystostomy was performed with clear yellow bile drained. Cholecystectomy was performed 4 weeks later revealing chronic cholecystitis and stones. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 10. 57-year-old woman with history of coronary artery disease, chronic kidney disease and COVID-19 pneumonia who developed abdominal pain and an elevated lipase. Axial T2-weighted image with fat saturation reveals hyperintense edema and fluid surrounding the pancreas (arrowheads), trace peripancreatic and left perirenal ascites, and gallbladder sludge (arrow). No gallstones were seen on ultrasound (not shown).

Fig. 11. 44-year-old man with diabetes and mild obesity hospitalized with COVID-pneumonia who developed acute kidney injury requiring dialysis and acute respiratory distress syndrome. His liver enzymes and lipase levels increased. Right upper quadrant ultrasound and non-contrast CT of the abdomen and pelvis were notable for increased hepatic and renal echogenicity (not shown). Balanced Turbo Field Echo (BTFE) axial MRI image shows mild T2 hyperintense stranding of the peripancreatic fat (arrowheads) surrounding the pancreatic tail. Mild hepatic steatosis was also present (not shown).
Fig. 12. 68-year-old woman with history of diabetes, hypertension and asthma presented to the hospital with COVID-19 pneumonia and elevated creatinine due to acute kidney injury. (a,b) Sagittal gray-scale ultrasound images of the right and left kidneys show increased renal parenchymal echogenicity and loss of corticomedullary differentiation with preserved cortical thickness.

Fig. 13. 65-year-old woman with COVID-19 pneumonia presented with elevated creatinine and acute kidney injury. Her past medical history was notable for hypertension and remote history of breast cancer. (a) Axial and (b) coronal contrast-enhanced CT images show patchy mottled inhomogeneous renal enhancement of both kidneys that are of normal size.

Fig. 14. 63-year-old man with past medical history of diabetes and hypertension, presented with COVID-19 pneumonia and two days of dysuria and hematuria. (a) Axial and (b) coronal contrast-enhanced CT images demonstrate marked mural thickening of the urinary bladder with mild adjacent perivesicular stranding. The patient has a penile prosthesis with a reservoir (asterisk) in the right anterior pelvis.
cases is therefore unknown and may be infectious, ischemic or due to an alternative cause.

Finally, it has also been reported that many patients with abdominal complaints lack abdominal imaging findings. In a study of abdominal CT scans of 23 patients whose lung bases had findings typical of COVID-19 and presented with abdominal complaints, there were no bowel abnormalities detected [62]. In a larger study of abdominal CT scans of hospitalized patients with COVID-19, 43% lacked abdominal imaging findings [14]. Of those who lacked abdominal findings in the study, 64% had basilar lung findings on CT. In another study of 43 hospitalized COVID-19 patients who underwent CT for abdominal complaints, 63% had no abdominal abnormality [63]. Therefore, it is not clear how often COVID-19 patients have relevant bowel involvement when symptomatic. Since abdominal symptoms are common, it can be postulated that some cases are due to nonspecific viral-induced pain or referred symptoms from basilar pneumonia.

2.4.1. Bowel imaging patterns of COVID-19

The most common and consistently reported imaging manifestations of COVID-19 affecting the bowel include mural thickening, non-specific ileus, fluid-filled colon, and pneumatosis intestinalis. Portal vein gas and pneumoperitoneum are less commonly seen [61, 64]. In a retrospective review of 141 COVID-19 patients in the ICU, 56% had clinically or radiologically diagnosed ileus, 2% had Ogilvie-like syndrome, 4% had bowel ischemia (3% small bowel, 1% small and large bowel and 1% cecal), 11% had GI bleeding and 4% had Clostridium difficile colitis [60]. Out of 81 hospitalized COVID-19 patients who underwent abdominal CT, 24% had intestinal findings of which colorectal thickening (5%), small bowel thickening (12%), and ileus (18%) were the most common, while pneumatosis (1%) and perforation (1%) were relatively rare [64]. In a retrospective study of 42 hospitalized COVID-19 patients who underwent CT, 31% had bowel wall abnormality [4]. Small bowel thickening was reported in 12%, all of whom were in the ICU. Colonic or rectal thickening was reported in 17%, of which nearly half were in the ICU. In another larger retrospective study of hospitalized COVID-19 patients who underwent CT for abdominal symptoms, 57% had positive abdominal imaging findings [14]. Bowel wall thickening was found at a lower rate of 15%, including mostly colonic and small bowel, with rare cases of esophageal and gastric thickening. An even smaller rate of bowel abnormalities was reported in a retrospective study of 32 hospitalized COVID-19 patients who underwent CT, where only 7% had nonspecific enteritis, with pneumatosis intestinalis in one patient [63].

Colonic mural thickening on CT has been reported in a patient with

Gastrointestinal symptoms in COVID-19 are relatively frequent. In a large meta-analysis of 43 studies of gastrointestinal manifestations of COVID-19 including over 18,000 patients, diarrhea was the most common GI symptom (11.5%), followed by nausea and vomiting (6.3%), and abdominal pain (2.3%) [59]. Among symptomatic patients, 17.5% had severe COVID-19 illness and 9.8% had a milder illness. In a retrospective study of 141 patients with severe COVID-19 in the ICU, 45% had gastrointestinal symptoms on admission including abdominal pain, diarrhea and vomiting [60]. In a meta-analysis of 36 studies reporting abdominal imaging in COVID-19, 16% of patients presented solely with gastrointestinal symptoms [61].

Gastrointestinal symptoms in COVID-19 may be due to hepatobiliary or enteric involvement and, in some, may be due to side effects of drug therapy or advanced sepsis. In addition, when enteric involvement occurs, the mechanism of bowel disease remains unclear with postulations including cytokine storm and inflammation, edema, or ischemia [61]. Further studies are needed to determine if there is a direct correlation between viral entry into enterocytes and imaging findings of enteritis or colitis, as mild cases are managed without operative intervention or definitive tissue diagnosis. The origin of bowel involvement in mild

Fig. 15. 69-year-old woman with history of hypertension, coronary artery disease and congestive heart failure presented to the Emergency Room with cough and chest tightness. She was diagnosed with COVID-19 pneumonia and found to have acute kidney injury. (a) Coronal contrast-enhanced CT image shows multiple wedge-shaped non-enhancing defects in the left kidney (arrowheads). Also seen is perinephric fat stranding around the right kidney with thickening of the adjacent Gerota’s fascia (arrows). (b) A more anterior coronal contrast-enhanced CT image shows a focal hypodense filling defect in the proximal left renal artery (arrow) consistent with thrombus.

Fig. 16. 71-year-old woman from a nursing home with history of dementia, schizophrenia and obstructive sleep apnea, found to be COVID-19 positive and presented to the Emergency Room unresponsive and with acute kidney injury. Axial contrast-enhanced CT image shows a hypodense filling defect distending the left renal vein consistent with non-occlusive renal vein thrombus (arrow).
symptomatic colitis in COVID-19 including one patient with hemorrhagic colitis confirmed on colonoscopy [65, 66]. Mucosal hyper-enhancement and mural thickening of the colon, mild mesenteric vascular congestion and small adjacent lymph nodes have been reported on CT in patients with colitis [67].

Finally, Horvat et al. found the presence of intestinal findings on CT in hospitalized COVID-19 patients positively correlated with a higher risk of worse clinical outcome including death or assisted ventilation [64].

2.4.2. Ileus

Ileus can manifest as gaseous distention of the small bowel, colon or both and is relatively common in hospitalized COVID-19 patients (Fig. 19). Kaafarani et al. reported that 56% of patients in their case series of 141 patients with severe COVID-19 requiring ICU care had a clinical or radiographic diagnosis of ileus [60]. The pathophysiology of ileus in COVID-19 is likely multifactorial. In severely ill COVID-19 patients, ileus is commonly caused by metabolic and/or electrolyte derangements but may also be reactive to other complications of COVID-19 [60, 68] or due to direct viral entry into enterocytes with resultant intestinal inflammation and ensuing ileus [68]. A few cases of severe colonic ileus have been reported in patients with severe pulmonary COVID-19 infection [68, 69], some of which were complicated by bowel ischemia [68, 69] and some of which were indistinguishable from Ogilvie syndrome [69].

2.4.3. Mesenteric Ischemia

Acute mesenteric ischemia is a serious and not uncommon complication of COVID-19 infection with a high mortality. It is theorized to

Fig. 17. 58-year-old male with history of hypertension and diabetes presented to the Emergency Room with worsening abdominal pain who tested positive for SARS-CoV2 1 week ago and lacked respiratory symptoms. (a) Axial and (b) coronal contrast-enhanced CT demonstrates multiple geographic wedge shaped non-enhancing splenic defects (arrowheads). (c) Axial contrast-enhanced CT 4 months later shows small linear band like areas of hypoattenuation with overlying capsular retraction consistent with scarring (arrowheads).

Fig. 18. 69-year-old man with history of atrial fibrillation hospitalized with COVID-19 pneumonia that developed a cerebrovascular attack in the ICU and required intubation for respiratory compromise. Prior to PEG placement CT of the abdomen and pelvis was performed to assess his anatomy. Axial contrast-enhanced CT image demonstrates a large wedge-shaped non-enhancing splenic infarct (asterisk) and diffuse hypodense filling defect in the splenic artery (arrows) consistent with thrombus. Enhancing splenic vein is noted (arrowhead). The patient did not survive.
Clinical Imaging 80 (2021) 88–110

and abdominal pain who tested positive for SARS-CoV-2. Supine portable radiograph shows mild prominence of air-filled small bowel that is minimally distended and mild prominence of non-dilated segments of colon consistent with ileus. No further imaging was performed. The patient was treated conservatively with supportive therapy and discharged 3 days later.

occur secondary to viral-induced hypercoagulability or thromboinflammation leading to thrombosis, as opposed to direct viral infection of the gastrointestinal tract [70,71]. Patients with mesenteric ischemia classically present with pain out of proportion to their physical exam and other gastrointestinal symptoms such as vomiting and diarrhea [71]. It is surmised that mucosal bowel ischemia expedites viral spread from the bowel wall leading to more rapid clinical deterioration because of the sudden increase in viral load [72]. If COVID-19 patients present with suspicious symptoms, there should be a low threshold to initiate a search for acute mesenteric ischemia with CT angiogram of the abdomen and pelvis.

Acute mesenteric ischemia can be caused by thromboembolic arterial or venous occlusion of medium or large mesenteric vessels or by microthrombosis of small vessels. A systematic literature review of studies reporting mesenteric ischemia in COVID-19 patients who had at least one gastrointestinal finding on imaging, defined as mesenteric arterial or venous thromboembolism or signs of small bowel ischemia, yielded 22 studies and 31 patients [73]. Nine (29%) had superior mesenteric arterial thromboembolism, 6 (19%) had occlusive thrombosis of the portal system or superior mesenteric vein and 16 (52%) had no visible vascular occlusion. More than two-thirds (64%) of all patients required laparotomy and bowel resection. The overall mortality was 39%. In this meta-analysis, almost half of patients with bowel ischemia had macrovascular arterial/venous thrombosis and half did not.

Imaging findings of COVID-19 related bowel ischemia on CT angiogram of the abdomen and pelvis are not unique and include mural thickening, a targetoid mural enhancement pattern, absent or diminished mural enhancement, mural hyperenhancement, ileus [Fig. 20], mesenteric vascular engorgement, mesenteric fat stranding and ascites. Pneumatosis and/or portomesenteric venous gas may reflect ischemia or infarction, but when seen together typically indicate infarction [74,75] [Fig. 21]. Arterial filling defects or zones of vascular narrowing may occur in arterial ischemia with preservation or thinning of bowel wall thickness. Venous filling defects may occur in venous ischemia typically with associated mesenteric venous engorgement, mural thickening and ascites. In nonocclusive mesenteric ischemia, bowel wall may be normal or thickened due to reperfusion. Mesenteric fat stranding and ascites are also common [74].

A few CT imaging reports of mesenteric ischemia in COVID-19 with confirmed bowel necrosis on surgical intervention have been reported. These include one case of non-enhancing distal ileal loops with adjacent free air and patent mesenteric vessels [76] and two cases of small bowel pneumatosis or portal venous gas suggestive of ischemia [4]. All three patients were reported to have yellow discoloration of the necrotic bowel on surgical exploration [4,76]. The first patient had unsalvageable necrotic bowel from the ligament of Treitz to the transverse colon and died shortly after surgery with presumed microvascular thrombosis [76]. One of the other two patients underwent small bowel resection, revealing patchy necrosis ranging from mucosal to full-thickness necrosis with submucosal arteriolar microthromboses [4].

Finally, pneumatosis or portal venous gas is reported in COVID-19 patients with bowel ischemia in up to 20% (4 of 20) of ICU patients, and is typically considered a marker for possible mesenteric ischemia [4]. However, in the absence of clinical symptomatology, like in non-COVID-19 patients, it may not on its own indicate ischemia or mandate surgical intervention. Meini et al. report a patient hospitalized for COVID-19 pneumonia that was successfully managed conservatively for asymptomatic intraperitoneal air bubbles and pneumatosis of the cecum and ascending colon noticed on chest CT performed for pulmonary embolism [77]. The etiology was theorized to be bowel wall injury and gut flora impairment during SARS-CoV-2 infection.

2.4.4. Ischemic colitis

Ischemic colitis has been reported rarely in patients hospitalized with COVID-19 illness with bloody diarrhea. In one case it was attributed to shock and hemodynamic compromise triggered by small vessel vasocostriction and mesenteric hypoperfusion [78] and in the other to inflammatory cytokine storm in a patient with risk factors for ischemic colitis but without hemodynamic compromise [79].

2.4.5. Pneumoperitoneum

Pneumoperitoneum in hospitalized COVID-19 patients has many causes including recent surgery, iatrogenic procedural trauma, bowel perforation, ischemia, and benign causes such as barotrauma in ventilated patients. Benign pneumomediated pneumoperitoneum can be due to pulmonary interstitial emphysema, known as the Macklin effect [80]. In the setting of barotrauma, typically due to invasive mechanical ventilation, alveoli can rupture leading to small pockets of air tracking along the peribronchovascular sheaths into the mediastinum. Once air collects within the mediastinum, it can dissect into the peri toneal cavity, causing pneumoperitoneum via major diaphragmatic ports [Fig. 22]. Alternatively, even if pneumomediated is absent, air can track directly through pleural or diaphragmatic defects leading to isolated pneumoperitoneum [81]. Duarte et al. report a case of pneumoperitoneum in a hospitalized COVID-19 patient who developed pulmonary interstitial edema from nasal cannula oxygen supplementation leading to benign pneumoperitoneum [81]. Intrathoracic barotrauma has been reported in 15% of COVID-19 patients on assisted mechanical ventilation and is more likely to occur in younger patients [82].

When unexpected pneumoperitoneum is detected in a COVID-19 patient on chest radiograph or abdominal imaging, it is essential to rule out potential bowel perforation or ischemia. If no cause is determined on abdominal CT, the patient should be observed closely to ensure bowel perforation or ischemia was not missed, and that the pneumoperitoneum is regressing. Given the high morbidity and mortality associated with exploratory laparotomy in hospitalized COVID-19 patients, there should be a high threshold for surgical intervention [81]. In certain situations, if a chest CT is performed, the Macklin effect can be confirmed by visualizing thin linear collections of air tracking along the bronchovascular sheath.
2.4.6. GI bleeding

Although the exact incidence of GI bleeding in COVID-19 is unknown, GI bleeding is not uncommonly observed in hospitalized COVID-19 patients, and in some cases may be the primary indication for abdominopelvic CT scan. In one retrospective study, 5% of hospitalized COVID-19 patients had GI bleeding as the indication for abdominal CT scan [4]. Patients may also present with symptoms of perforated gastric or duodenal ulcers, which has been attributed to stress-related mucosal damage in the setting of severe illness or anticoagulation, rather than direct infection or ischemia of the gastrointestinal tract [83]. In a large case series of 4871 patients in Northern Italy, 23 patients developed upper GI bleeds (0.5%), 78% of whom were on anticoagulation at the time bleeding, including 44% on full dose anticoagulation [84]. While most patients in the case series developed bleeding during their hospital course, 26% of patients initially presented to the emergency room for GI bleeding and then tested positive for COVID-19 infection, suggesting that in some cases bleeding may be directly due to COVID-19 infection rather than stress-related mucosal damage or anticoagulation [84].

A multicenter international study of 114 endoscopies performed on COVID-19 patients for acute GI bleeds, found that 25% of bleeds were caused by ulcers, 16% by erosive/ulcerative gastro-duodenopathy and 9% by petechial or hemorrhagic gastropathy [85]. Utilizing multivariate regression analysis, the authors found that ICU admission, pre-existing frailty, and extended hospitalization had no impact on the risk of a positive endoscopy finding [85].

Dedicated CT angiogram with a GI bleeding protocol, including non-contrast, arterial and portal venous phase images can detect foci of active bleeding at a rate of 0.3–0.5 ml/min which is less sensitive than RBC scanning (0.1–0.5 ml/min) but more sensitive than fluoroscopic angiography (0.5–1.0 ml/min) [86]. Alternatively, on a dual energy scanner, images maybe acquired in the arterial and portal venous phase with reconstruction of a virtual non-contrast image set [86]. On non-contrast exam, luminal blood product is hyperdense with attenuations ranging from 30 to 45 HU when unclotted and from 45 to 70 HU when clotted [87,88]. Active extravasation of contrast appears as an area of intraluminal enhancement on arterial phase images that changes shape and attenuation on portal venous phase [89] (Artigas). In patients with intermittent bleeding or in stable patients with elevated creatinine, a technetium 99m $^{99m}$Tc nuclear medicine scan with a sulfur colloid or red blood cell pharmaceutical agent may be used as an alternative imaging modality. $^{99m}$Tc scintigraphy has a high sensitivity but poor anatomic localization of acute GI bleed [90]. CT angiogram has the
Fig. 21. 61-year-old man with no significant past medical history in the ICU for one month for respiratory failure due to COVID-19 pneumonia underwent CT scan of the chest, abdomen and pelvis because of persistent fever and leukocytosis despite broad spectrum antibiotics. (a) Supine scout shows bilateral interstitial infiltrates and marked colonic ileus. (b) Axial contrast-enhanced CT image shows portal venous gas (arrow) in the periphery of the left hepatic lobe. (c) Coronal CT images shows pneumatosis of the entire right colon (arrow) and a distal ileal loop (arrowhead) with mild mesenteric haziness. (d) Axial CT image shows extensive distal ileal pneumatosis (arrowhead) with adjacent branching mesenteric venous gas (thin arrows). Despite the findings of bowel ischemia, due to the patient's advanced septic condition, he was not a surgical candidate and died the following day. Additional imaging during his hospital course confirmed evidence of acute kidney injury with (e) longitudinal ultrasound image of his left kidney showing increased cortical echogenicity with increased conspicuity of the pyramids (arrowheads). He also had signs of liver injury with rising liver function tests and (f) longitudinal ultrasound image of the right hepatic lobe showing increased echogenicity suggestive of steatosis.
2.4.7. Pseudomembranous colitis

*Clostridium difficile* colitis is frequently seen in severely ill COVID-19 patients after treatment with broad-spectrum antibiotics, which were given frequently early on in the pandemic and are still routinely given to COVID-19 patients with severe sepsis. In addition to antibiotic use, direct infection of enterocytes by the SARS-CoV-2 virus may disrupt the gut microbiome, increasing a patient's susceptibility to gastrointestinal infection, including *Clostridium difficile* [91]. Elderly patients, especially those living in long-term care facilities, have both an increased risk of severe COVID-19 illness and baseline elevated rates of *Clostridium difficile* colonization. This confounds our understanding of the true impact of COVID-19 infection on the development of *Clostridium difficile* colitis [91]. In a retrospective clinical laboratory review of hospitalized patients with *Clostridium difficile* infection, 9 patients co-infected with COVID-19 were found, all of whom had severe COVID-19 illness and developed symptomatic *Clostridium difficile* colitis during their hospital course, all related to antibiotic administration [92].

Pseudomembranous colitis should be suggested whenever abdominopelvic CT scan shows a pattern of long segment colitis [Fig. 25] most commonly involving the rectosigmoid but which can be also be segmental involving the right or transverse colon or pan-colonic in extent. It is characterized by a more extensive pattern of circumferential mural thickening than other causes of colitis, with low attenuation intramural edema, and associated features including the “accordion sign,” the “target sign,” pericolonic stranding and ascites. Mural

Fig. 22. 67-year-old man with stage III colon cancer hospitalized for COVID-19 pneumonia requiring mechanical ventilation for worsening respiratory distress. (a) Portable chest radiograph shows bilateral infiltrates consistent with pneumonia, with subcutaneous emphysema in the right axilla and neck (asterisk), pneumoperitoneum under the right hemidiaphragm (arrowheads), and small pneumomediastinum (arrows). Bilateral cervical central lines and endotracheal tube are present. (b) Subsequent non-contrast CT image performed with oral contrast via a nasogastric tube showed no extravasation of oral contrast. Pneumoperitoneum ventral to the liver (arrow) and tracking along the gastrohepatic ligament and subjacent left precrural retroperitoneum (arrowheads) is noted. (c) More caudal CT image shows continuous tracking of retroperitoneal gas in the left retroperitoneum (arrowheads) anterior to the left psoas and in the left posterior pararenal space and left paracolic gutter. Small foci of extraluminal gas are visible in the right anterior abdomen. (d) Coronal CT image of the chest, abdomen and pelvis with lung windows shows the tracking nature of the pneumomediastinal air (arrowheads) coursing below the diaphragm (black arrows) into the left retroperitoneum and left paracolic gutter. Subcutaneous emphysema in the right axilla is noted (black asterisk). Bilateral pneumonia is noted and the nasogastric is partially visualized.
thickening is marked with a reported mean of 15 mm (range 3–32 mm), and is often irregular and shaggy [93].

3. Multisystem inflammatory syndrome in the pediatric population

Children with COVID-19 experience far less severe pulmonary disease than adults and account for only a minority of confirmed COVID-19 cases (2–8%) [94,95]. Although the majority of symptomatic children with COVID-19 have a respiratory illness, gastrointestinal symptoms have been reported in 33–35% of cases, with vomiting, diarrhea and abdominal most common [96,97]. This review will focus on the multifaceted post-infectious clinical and imaging manifestations of COVID-19 unique to children, coined multisystem inflammatory syndrome in children (MIS-C).

Although infected children tended to be only mildly symptomatic during the early months of the pandemic, by April and May of 2020, several medical centers in Europe and North America reported children with a multiorgan Kawasaki disease-like syndrome, consisting of fever and mucocutaneous rash, sometimes with features of toxic shock syndrome [98–100]. This syndrome was previously given various overlapping definitions, however as more cases subsequently arose around the globe, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have given this entity the preferred label of “Multisystem Inflammatory Syndrome in Children” (MIS-C) [101,102].

MIS-C is an acute febrile illness characterized by inflammation, gastrointestinal symptoms, and cardiac manifestations [103,104]. Although SARS-CoV-2 is not definitively known to cause MIS-C, temporal occurrences to outbreaks in Europe and America are highly suggestive of a link, and some cases even occur in the presence of an acute respiratory infection [104,105]. Some MIS-C patients test positive for SARS-CoV-2 IgM and IgG antibodies, rather than testing positive for the virus on RT-PCR, and a minority of patients have recorded COVID-19 symptoms a few weeks prior to onset of MIS-C [95,103,106–108]. These findings raise the possibility that MIS-C represents a post-infectious immune-mediated phenomenon, rather than an acute viral infection [95,107,109].

While some features of MIS-C, such as fever, conjunctival injection, oropharyngeal erythema, and maculopapular rash, overlap with Kawasaki disease, the two syndromes appear to be separate entities [96,104,107]. MIS-C is characterized by various elevated inflammatory laboratory values (erythrocyte sedimentation rate, C-reactive protein, procalcitonin, interleukin-6, lactate dehydrogenase, D-dimer, and lymphopenia), myocardial dysfunction (elevated troponins, elevated pro-B-type natriuretic peptide, depressed ejection fraction), hypotension, shock, and acute kidney injury [98,108–112]. Kawasaki disease has lower rates of myocardial involvement than MIS-C, and is more frequently associated with coronary artery aneurysms. Kawasaki disease typically presents before 5 years of age, with the highest incidence of disease in Asia. In contrast, MIS-C usually occurs in older children and adolescents, and has not been reported in China or Japan.

Treatment of MIS-C is both supportive and directed, consisting of fluid resuscitation, vasopressors and ionotropic support, anticoagulation, intravenous immune globulin (IVIG), glucocorticoids, and other immunomodulatory and antiviral drugs [95,98,105,106,109,110]. Critical cases may require mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Despite the severity of MIS-C at initial presentation, short-term outcomes are favorable, with the majority of patients recovering between a few days up to two weeks [110,113].

The diagnosis of MIS-C is made on clinical grounds, and imaging in not routinely indicated. However, imaging may be requested to exclude other acute pathologies, and imaging abnormalities are associated with fulminant illness [104]. While the vast majority of MIS-C patients experience gastrointestinal symptoms, a wide-ranged incidence...
of respiratory symptoms has been reported [105, 106, 108–110, 112]. Although this review is focused on the extra-
pulmonary manifestations of COVID-19, the cardiothoracic imaging
findings of MIS-C will be included because the majority of MIS-C pa-
tients have pulmonary findings that are slightly different than those of
routine COVID-19 pneumonia and may have associated cardiac
sequelae.

### 3.1. Thoracic manifestations of MIS-C

The most common respiratory complaint in MIS-C is tachypnea,
although some patients may progress to respiratory failure requiring
mechanical ventilation, likely secondary to shock and cardiac

---

**Fig. 25.** 74-year-old morbidly obese woman with history of breast cancer and prolonged ICU hospitalization for severe COVID-19 pneumonia causing acute respiratory failure. One week after discharge to a nursing home, she was readmitted to the hospital for fever, hypotension and diarrhea. (a) Coronal non-contrast CT image with oral contrast shows prominent right and left colonic mural thickening (arrows) which involved the entire colon (not shown). (b) Axial image better shows the extent of mural thickening in the right colon (arrow) due to luminal contrast. *Clostridium difficile* infection was confirmed and she improved after treatment with oral Vancomycin and IV Flagyl. Her course was subsequently further complicated by gastrointestinal bleeding and retroperitoneal hemorrhage due to anticoagulation. (c) Axial non-contrast CT image shows hyperdense content expanding both psoas muscles (arrows), and in the right paracolic gutter (arrowhead).

**Fig. 26.** Chest radiographs in two patients with MIS-C. 9-year-old girl with previously healthy girl who presented with cardiogenic shock and acute renal failure. Frontal chest radiograph shows symmetric hazy airspace opacities, increased interstitial markings, and bilateral small pleural effusions.

**Fig. 27.** Chest radiographs in two patients with MIS-C. 9-year-old boy with history of asthma, who presented with high fever, rash and abdominal pain. Frontal chest radiographs shows mild cardiomegaly and bilateral symmetric central consolidative airspace opacities.
dysfunction [106,108,110,114]. While initial chest radiographs can be normal, as the disease progresses, common radiographic findings include bilateral diffuse airspace opacities with basilar predominance, peribronchial thickening or interstitial opacities, bilateral pleural effusions, and cardiomegaly [112,114–117] (Figs.26,27). The pulmonary opacities tend to be hazy and symmetric, suggesting that they reflect pulmonary edema, ARDS, and/or third spacing. These phenomena may be secondary to cardiac dysfunction, the hyperinflammatory status of the patient, or possibly even the sequelae of aggressive fluid resuscitation [112,116–118]. Although chest radiograph findings in MIS-C can overlap with acute COVID-19 pneumonia, COVID usually presents as non-diffuse peripheral or subpleural opacities without pleural effusions and MIS-C usually presents as diffuse opacities with lower lobe predominance with pleural effusions [112,117]. It is interesting to note that patients with MIS-C may demonstrate abnormalities on chest radiographs even in the absence of lower respiratory tract symptoms [114,117].

Chest CT is not routinely performed in MIS-C, but may be indicated in patients with sepsis or suspected pulmonary embolism [114,116]. The most common chest CT findings are bibasilar consolidation with atelectasis and bilateral pleural effusions, with diffuse ground-glass opacity, septal thickening, and mild hilar lymphadenopathy less common [114] (Fig. 26).

3.2. Cardiac manifestations of MIS-C

Echocardiography is routinely performed at baseline and in follow-up of patients with MIS-C. The most common finding is depressed left ventricular ejection fraction, with other findings including valvular regurgitation and small pericardial effusion [110,111,119,120]. Coronary artery ectasia or aneurysms have been seen in a minority of patients on echocardiogram and cardiac CT [111,114,121]. Postinfectious
myocarditis characterized by diffuse myocardial edema and hyperemia without evidence of fibrosis on delayed gadolinium-enhanced images has been reported on cardiac MRI [122].

3.3. Vascular manifestations of MIS-C

While adult COVID-19 patients are vulnerable to vascular complications, it remains unclear whether children with SARS-CoV-2 infection have an increased risk of thrombosis [123–127]. Data on thrombotic complications in pediatric COVID-19 and MIS-C is limited, likely due to its low incidence, and currently published guidelines for thromboprophylaxis in children are extrapolated from the adult population. The highest reported rate of symptomatic imaging-confirmed thromboembolic disease (deep venous thrombosis or pulmonary embolism) in one multicenter registry of MIS-C was 7% [106]. It is thought that children with COVID-19 and/or MIS-C who experience hospital-associated thrombotic events have markedly elevated plasma D-dimer levels, or have one or more superimposed risk factors (e.g., prior history of venous thrombosis, indwelling central line, active malignancy, etc) [124,126]. Imaging is not necessarily required prior to initiation of therapy if a thromboembolic event is suspected, but can be obtained at the time of discharge, in order to guide the length and intensity of the anticoagulation regimen [125].

3.4. Abdominal manifestations of MIS-C

Since patients with MIS-C most commonly present with gastrointestinal symptoms, often mimicking acute appendicitis, abdominal imaging is sometimes obtained even prior to recognition of the MIS-C diagnosis [98,114,128]. Commonly reported findings on abdominal radiographs, ultrasound, and CT include an ileus bowel gas pattern, mild ascites, gallbladder wall thickening, bowel wall thickening, mesenteric lymphadenopathy, mesenteric edema or inflammatory change, and urinary bladder wall thickening [114,116,117,129] (Figs. 29,30,31). Bowel wall thickening, lymphadenopathy, and mesenteric changes can occur anywhere in the abdomen but are most commonly located in the right lower quadrant [130] (Fig. 32). A minority of patients has also demonstrated hepatosplenomegaly, splenic infarction, and increased renal echogenicity [114,116,131]. Acute hepatitis, defined as elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, was found in 43% of subjects in a single-center report, and may account for some of the abdominal ultrasound findings in MIS-C such as hepatomegaly, gallbladder wall thickening, and ascites [132].

3.5. Neurologic manifestations of MIS-C

Of patients with MIS-C who have undergone brain imaging, MRI is usually normal, however there are isolated reports of cortical signal abnormalities, papilledema, and infarct [114,117]. Cervical

![Fig. 30.](image)

8-year-old girl with MIS-C who presented with abdominal pain, diarrhea, fever, tachycardia and hypotension. Coronal contrast-enhanced CT image demonstrates a cluster of enlarged mesenteric lymph nodes in the right lower quadrant (arrows). There is diffuse mild fluid distention of small and large bowel consistent with ileus.

![Fig. 31.](image)

13-year-old boy with MIS-C who presented with abdominal pain, vomiting, diarrhea, fever, hypotension and elevated liver function tests. (a) Coronal contrast-enhanced CT image demonstrates mural thickening of the ascending colon (arrows) and terminal ileum (TI). Gallbladder wall thickening is noted. (b) Coronal image in a more posterior location shows a chain of enlarged mesenteric lymph nodes (thin arrows), with hazy infiltration of the mesentery (arrowheads). There is also small pelvic ascites (thick arrows).
1. WHO Coronavirus Disease (COVID-19) Dashboard. WHO COVID-19 homepage. https://covid19.who.int.

2. Benedetti C, Waldman M, Zaza G, Riella LV, Cravedi P. COVID-19 and the kidneys: an update. Front Med 2020;7:423. https://doi.org/10.3389/fmed.2020.00423 [PMID: 32793615; PMCID: PMC7385132].

3. Revzin MV, Raza S, Warhavsky R, D’Agostino C, Srivastava NC, Bader AS, et al. Multisystem imaging manifestations of COVID-19, part 1: viral pathogenesis and pulmonary and vascular system complications. RadioGraphics 2020;40(6):1574–99. https://doi.org/10.1148/rg.2020200149.

4. Intrabasri R, Som A, Li MO, Carey DE, Anderson MA, Blake MA, et al. Abdominal imaging findings in COVID-19: preliminary observations. Radiology 2020 Oct; 297(1):E215. https://doi.org/10.1148/radiol.2020200190 [Epub 2020 May 11. PMID: 32391742; PMCID: PMC7508000].

5. Kumar A, Faqiq MA, Pareek V, Raza K, Narayan RK, Prasoon P, et al. Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. Med Hypotheses 2020;144:110271. https://doi.org/10.1016/j.mehy.2020.110271.

6. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020;18(9):2128–2130.e2. https://doi.org/10.1016/j.cgh.2020.04.040.

7. Revzin MV, Raza S, Srivastava NC, Warhavsky R, D’Agostino C, Malhotra A, et al. Multisystem imaging manifestations of COVID-19, part 2: from cardiac complications to pediatric manifestations. Radiographics 2020;40(7):1866–92. https://doi.org/10.1148/rg.2020200195 [PMID: 33316488; PMCID: PMC7646410].

8. Lei P, Zhang L, Han P, Zheng C, Song Q, Shang H, et al. Liver injury in patients with COVID-19: clinical profiles, CT findings, and the correlation to the severity with liver injury. Hepatol Int 2020;14:733–42. https://doi.org/10.1007/s12876-020-10087-1.

9. Zhao JN, Fan Y, Wu SD. Liver injury in COVID-19: a minireview. World J Clin Cases 2020;8(19):4303–10. https://doi.org/10.12998/wjcc.v8.i19.4303.

10. Díaz LA, Idaaloa F, Camnita M, Candia R, Cabrera D, Barrera F, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data. World J Gastroenterol 2020 Dec; 26(26):7693–706. https://doi.org/10.3748/wjg.v26.i47.7693 [PMID: 33505145; PMCID: PMC7790052].

11. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020 May;5(5):428–38. https://doi.org/10.1016/S2468-1253(20)30057-1 [Epub 2020 Mar 4. PMID: 32145190; PMCID: PMC7519165].

12. Abdelmoten MA, Alikandari BM, Gupta VK, Elbeheiry AA. Diagnostic value of abdominal sonography in confirmed COVID-19 intensive care patients. Egypt J Radiol Nucl Med 2020;51(1):198. https://doi.org/10.1016/j.ejrm.2020.06.019.

13. Medeiros AK, Barbian CC, Cruz JR, et al. Higher frequency of hepatic steatosis at CT among COVID-19-positive patients. Abdom Radiol 2020;45(9):2748–54. https://doi.org/10.1007/s00261-020-02648-7.

14. Goldberg-Stein S, Fink A, Paroder V, Kohl M, Yee J, Chemyuk V. Abdominopelvic CT findings in patients with novel coronavirus disease 2019 (COVID-19). Abdom Radiol 2020 Aug;45(9):2613–23. https://doi.org/10.1007/s00261-020-02669-2 [Epub 2020 Aug 6. PMID: 32761402; PMCID: PMC7406871].

15. Franco-Moreno A, Pinilla-Ruiz E, Montoya-Adarraga J, et al. Portal vein thrombosis in a patient with COVID-19. Thromb Res 2020;194:150–2. https://doi.org/10.1016/j.thromres.2020.06.019.

16. Borzajani R, Seraj SR, Fallah M, et al. Acute portal vein thrombosis secondary to COVID-19: a case report. BMC Gastroenterol 2020;20:386. https://doi.org/10.1186/s12876-020-01518-2.

17. Ofosu Andrew, Ramai Daryl, Novikov Anastasia, Sushma Venugopal. Portal vein thrombosis in a patient with COVID-19. Am J Gastroenterol September 2020;115(9):1545–6. https://doi.org/10.1038/s41395-020-00070-1.

18. Jafari SH, Naseri R, Khalili N, Haseli S, Bahmani M. Portal vein thrombosis associated with COVID-19: points to consider. JBR Case Rep 2020;6:230.200089.

19. Dane B, Smereka P, Wain R, Kim D, S Katz D. Hypercoagulability in patients with Coronavirus Disease (COVID-19): identification of arterial and venous thromboembolism in the abdomen, pelvis, and lower extremities. AJR Am J Roentgenol 2021 Jan;216(1):104–5. https://doi.org/10.2214/ajr.20.23617 [Epub 2020 Sep 22. PMID: 32603200].

20. Albasam SM, Iqbal P, Fikrey I, MIM Ibrahim, Qamara MS, Chappaona M, et al. Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report. Ann Med Surg 2020;60:434–7. https://doi.org/10.1016/j.amsu.2020.11.031.

21. Balbaspas A, Gkouda K, Meyer J, Beloza A, Borzajani A, McKee TA, et al. COVID-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall. J Hepatol 2020;73(6):1566–8. https://doi.org/10.1016/j.jhep.2020.08.020.

22. Somucu E, Kara Y, Yuzikova MC, Bozdag F, Yildiz ZB, Ozkan C, et al. Periampullary cholecystotomy instead of laparotomy to treat acute cholecystitis during the COVID-19 pandemic period: single center experience. Ulus Travma Acil Cerrahi Derg 2021;27(1):89–94 [English. doi: 10.4744/ucd.2021.06.09804. PMID: 33994471].

23. Campanile F, Poddà M, Areeze A, Botteri E, Sartori A, Guerrieri M, et al. World J Emerg Surg 2020;15:38. https://doi.org/10.1186/s12871-020-00317-0.

24. Peckham-Coooper A, Cee PO, Clarke RW, Burke J, Lee MJ. The role of cholecystostomy drains in the management of acute cholecystitis during the
Clinical imaging 80 (2021) 88–110
D. Kanmaniraja et al.

[27] Cheung S, Delgado Fuentes A, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19. J Clin Med 2020 May 11;9(5):1417. https://doi.org/10.3390/jcm9051417 [PMID: 32402321; PMCID: PMC7929069].

[28] Silver SA, Beaubien-Souligny W, Shah PS, Harel S, Blum D, Kishibe T, et al. The pathologic and experimental study. Radiology 1984;151(3):723-7.

[29] Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in COVID-19 patients. Thromb Res 2020;186:254-9. https://doi.org/10.1016/j.thromres.2020.04.013 [Epub 2020 Apr 10. PMID: 32291094; PMCID: PMC7723763].

[30] Fuentes IB, Qiu Y, King KL, Stevens JS, Husain SA, Radhakrishnan J, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int 2021;93:1. https://doi.org/10.1016/j.kint.2021.01.088 [83-98.e1, Epub 2020 Dec 9. PMID: 33319196; PMCID: PMC7723763].

[31] Readman-Jones AR, Qin L, King KL, Stevens JS, Husain SA, Radhakrishnan J, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep 2020 Jun 25;5(8):1149–60. https://doi.org/10.1016/j. kidintrep.2020.06.013 [PMID: 32775814; PMCID: PMC7314966].

[32] Nadine MK, Forni LG, Mehta RL, Connor Jr MJ, Liu KD, Ostermann M, et al. COVID-19 associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97(4):1092-40. https://doi.org/10.1016/j.kint.2020.08.049 [Epub 2020 Aug 25. PMID: 32864008; PMCID: PMC7459211].

[33] Mumm JM, Osterman A, Ruzichia S, Chilst S, Vilma T, Munker D, et al. Urinary frequency as a possibly overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis? Eur Urol 2020 Oct;78(4):624-8. https://doi.org/10.1016/j.eururo.2020.05.013 [Epub 2020 May 19. PMID: 32475749; PMCID: PMC7263674].

[34] Lamb LE, Dhar N, Timar R, Wang X, Chen X, Jiang C, et al. COVID-19 associated with urinary tract infection in critically ill COVID-19 patients. J Clin Med 2020 Jun 2;9(6):1417-8. https://doi.org/10.3390/jcm90601417 [PMID: 32096773; PMCID: PMC7992819].

[35] Post A, den Duursma ESR, Bakker SJL, de Haas RJ, van Meurs M, Egerod A, et al. Post COVID-19 pulmonary fibrosis: a case report. Radiology 2020;297:15-6. https://doi.org/10.1148/radiol.2020200154 [Epub 2020 Feb 13. PMID: 32195127; PMCID: PMC7855333].

[36] van der Velden MP, van der Horst RL, Mazza C, et al. COVID-19 associated with acute kidney injury: a possible underestimated and underdiagnosed complication. Nephrol Dial Transplant 2021;36:268-76. https://doi.org/10.1093/ndt/ggaa216 [Epub 2021 Feb 1. PMID: 33183302; PMCID: PMC7894226].

[37] Cheung S, Delgado Fuentes A, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19. Radiol Case Rep 2020;15(11):2449-57. https://doi.org/10.1016/j.endocr.2020.109240 [Epub 2020 Aug 26. PMID: 32920219; PMCID: PMC7644181].

[38] Huang Q, Li J, Lyu S, Liang W, Yang R, Zhang R, et al. COVID-19 associated with in-hospital death of patients with COVID-19. Kidney Int 2020 Mar 20;97(5):829-38. https://doi.org/10.1016/j.kint.2020.03.005 [Epub 2020 Mar 31. PMID: 32247631; PMCID: PMC7110296].

[39] Lee HS, Park EJ, Lee HJ, Lee JH, Lee KS, Kang KS, et al. COVID-19 associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97(4):1092-40. https://doi.org/10.1016/j.kint.2020.08.049 [Epub 2020 Aug 25. PMID: 32864008; PMCID: PMC7459211].

[40] Cheung S, Delgado Fuentes A, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19. Radiol Case Rep 2020;15(11):2449-57. https://doi.org/10.1016/j.endocr.2020.109240 [Epub 2020 Aug 26. PMID: 32920219; PMCID: PMC7448815].

[41] Fuentes IB, Qiu Y, King KL, Stevens JS, Husain SA, Radhakrishnan J, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep 2020 Jun 25;5(8):1149–60. https://doi.org/10.1016/j. kidintrep.2020.06.013 [PMID: 32775814; PMCID: PMC7314966].

[42] Cheung S, Delgado Fuentes A, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19. Am J Case Rep 2020;21:e927076. https://doi.org/10.1016/j.ajcr.2020.11.011 [Epub 2020 Nov 5. PMID: 33171364; PMCID: PMC7644181].

[43] Cheung S, Delgado Fuentes A, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19. Radiol Case Rep 2020;15(11):2449-57. https://doi.org/10.1016/j.endocr.2020.109240 [Epub 2020 Aug 26. PMID: 32920219; PMCID: PMC7448815].
hospital in the United States. Pediatr Radiol 2021;51:239-47. https://doi.org/10.1007/s00247-020-04830-x.

[116] Blumfield E, Levin TL, Kurtan J, Lee EY, Liszewski MC. Imaging findings in Multisystem Inflammatory Syndrome in Children (MIS-C) associated with coronavirus disease (COVID-19). AJR Am J Roentgenol 2021;216:507–17. https://doi.org/10.2214/aJR.20.24032.

[117] Fenlon Iii EP, Chen S, Rual-Shapiro CB, Jaramillo D, Maddocks ABR. Extracardiac imaging findings in COVID-19-associated multisystem inflammatory syndrome in children. Pediatr Radiol 2021:1–9. https://doi.org/10.1007/s00247-020-04929-1.

[118] Trout AT, Westra SJ. Imaging in support of the clinical diagnoses of COVID-19 and multisystem inflammatory syndrome in children. Pediatr Radiol 2021:1–2. https://doi.org/10.1007/s00247-021-05019-7.

[119] Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: a systematic review. eClinicalMedicine 2020;26:100527. https://doi.org/10.1016/j.eclinm.2020.100527.

[120] Theocharis P, Wong J, Pushparajah K, Mathur SK, Simpson JM, Pascault E, et al. Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19. Eur Heart J Cardiovasc Imaging 2020. https://doi.org/10.1093/ehjci/jeaa212.

[121] Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr 2021;180:307–22. https://doi.org/10.1007/s00431-020-03766-6.

[122] Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. Radiology 2020;297:e283–e288. https://doi.org/10.1148/radiol.2020202288.

[123] Del Borrello G, Giraudo I, Bondone C, Denina M, Garazzino S, Linari C, et al. SARS-CoV-2-associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost 2021;19:522–30. https://doi.org/10.1111/jth.15216.

[124] Sahn B, Eze OP, Edelman MC, Chougar CE, Thomas RM, Schleien CL, et al. Features of intestinal disease associated with COVID-related multisystem inflammatory syndrome in children. J Pediatr Gastroenterol Nutr 2021;72:384–7. https://doi.org/10.1097/jpg.0000000000002953.

[125] Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to Coronavirus Disease 2019: a single center experience of 44 cases. Gastroenterology 2020;159. https://doi.org/10.1053/j.gastro.2020.05.079 (1571-1574.e1572).

[126] Tullie L, Ford K, Bisharat M, Watson T, Thakkar H, Mullassery D, et al. Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children. Lancet Child Adolesc Health 2020;4:e19–20. https://doi.org/10.1016/s2352-4642(20)30165-6.

[127] Goldenberg NA, Socher A, Alhassan M, Blix T, Bonduel M, Jaffray J, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost 2020;18:3099–105. https://doi.org/10.1111/jth.15073.

[128] Karimi M, Bozorgi H, Zarei T, Bordbar M, Amanati A, Safaei A, et al. Antithrombotic prophylaxis in children and adolescents’ patients with SARS-CoV-2 (COVID-19) infection: a practical guidance for clinicians. Acta Biomed 2020;91:e2020170. https://doi.org/10.23750/abn.v91i14.10720.

[129] Loot M, Branchford B, Kim J, Self C, Nuss R. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer 2020;67:e28485. https://doi.org/10.1002/pbc.28485.

[130] Del Borrello G, Giraudo I, Bondone C, Denina M, Garazzino S, Linari C, et al. SARS-CoV-2-associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost 2021;19:522–30. https://doi.org/10.1111/jth.15216.

[131] Morparia K, Park MJ, Kalyanaraman M, McQueen D, Bergel M, Phatak T. Abdominal imaging findings in critically ill children with multisystem inflammatory syndrome associated with COVID-19. Pediatr Infect Dis J 2021;40: e82–3. https://doi.org/10.1097/INF.0000000000002967.

[132] Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report. Hepatology 2020;72:1522–7. https://doi.org/10.1002/hep.31526.